- Home
- RVT vs AUPH Comparison
RVT vs AUPH Comparison
Compare RVT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVT | AUPH |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RVT | AUPH |
|---|---|---|
| Price | $17.26 | $16.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 169.2K | ★ 740.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | ★ 2.95 | 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ $5.87 | $30.94 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $14.97 | $10.34 |
| 52 Week High | $19.12 | $19.25 |
Technical Indicators
Market Signals| Indicator | RVT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 50.60 |
| Support Level | $17.31 | $15.65 |
| Resistance Level | $18.73 | $16.40 |
| Average True Range (ATR) | 0.30 | 0.40 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 4.97 | 38.17 |
Price Performance
Historical ComparisonAbout RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.